"We have a program that focuses on specific microRNAs that may serve as unique therapeutic approaches for the treatment of PAD."
Brian H. Annex,
Brian Annex, MD, is board certified in internal medicine, cardiovascular diseases and interventional cardiology. Prior to his arrival at UVA in July 2008, Dr. Annex served as professor of medicine in the Division of Cardiovascular Medicine at Duke University School of Medicine. While at Duke, he also served as vice chief for the Division of Cardiovascular Medicine. He initiated and then served as director of vascular medicine at Duke as well as a staff cardiologist at the Durham Veterans Administration Medical Center.
Dr. Annex's laboratory is a true bench to bedside translational research laboratory that focuses on angiogenesis (the growth and proliferation of blood vessels from existing vascular structures) in the context of peripheral arterial disease (PAD). With this as a focus, he launched a research program that focuses on specific microRNAs that may serve as unique therapeutic approaches for the treatment of PAD in mouse, cell culture, and selected human studies. In addition, he has a continuing NIH funded program using adeno-associated virus-based gene therapy which has mouse, large animal, and human components. He also has two active projects in the area of computational modeling for angiogenesis in PAD. Finally, we have pure human based mechanism testing human studies.
Biotechnology and Biomolecular Engineering (Biomolecular Design, Cellular and Molecular Bioengineering)
Computational Systems Biology
Endothelial cell-by-cell profiling reveals temporal dynamics of VEGFR1 and VEGFR2 membrane-localization following murine hindlimb ischemia. Am J Physiol Heart Circ Physiol. 2013 Feb 1. [Epub ahead of print] Imoukhuede PI, Dokun AO, Annex BH, Popel AS.
Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. J Sex Med. 2013 Feb;10(2):362-9. doi: 10.1111/j.1743-6109.2012.02854.x. Ellati RT, Dokun AO, Kavoussi PK, Steers WD, Annex BH, Lysiak JJ.
Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. J Gene Med. 2012 Konkalmatt PR, Wang F, Piras BA, Xu Y, O'Connor DM, Beyers RJ, Epstein FH, Annex BH, Hossack JA, French BA.
Skeletal muscle-specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice. Am J Pathol. 2012 May;180(5):2156-69. doi: 10.1016/j.ajpath.2012.01.032. McClung JM, McCord TJ, Keum S, Johnson S, Annex BH, Marchuk DA, Kontos CD.
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Vasc Med. 2012 Apr;17(2):94-100. doi: 10.1177/1358863X11436334. Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, Hiatt WR, Dokun AO, Annex BH.
Exercise dose response in muscle. Int J Sports Med. 2012 Mar;33(3):218-23. doi: 10.1055/s-0031-1291323. Duscha BD, Annex BH, Johnson JL, Huffman K, Houmard J, Kraus WE.
Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study. Vasc Med. 2012 Feb;17(1):3-9. doi: 10.1177/1358863X11431837. West AM, Anderson JD, Epstein FH, Meyer CH, Hagspiel KD, Berr SS, Harthun NL, Weltman AL, Annex BH, Kramer CM.
A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv. 2011 Dec 1;78(7):1060-7. doi: 10.1002/ccd.23066. Perin EC, Silva G, Gahremanpour A, Canales J, Zheng Y, Cabreira-Hansen MG, Mendelsohn F, Chronos N, Haley R, Willerson JT, Annex BH.